Akebia Therapeutics Inc (AKBA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Akebia Therapeutics Inc (AKBA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7966
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF-PH inhibitor, a regulator for the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD). The company’s product pipeline includes AKB-5169, an oral treatment for inflammatory bowel disease. The company works in partnership with Otsuka Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, and Vifor Pharma Management Ltd for the development and commercialization of its pipeline products. The company operates in the US and Ireland. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Akebia Therapeutics Inc (AKBA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Akebia Therapeutics Raises US$41 Million In Series C Financing 13
Akebia Therapeutics Secures Additional US$4.1 Million In Series B Financing 15
Partnerships 16
Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 16
Merger 17
Akebia Therapeutics and Keryx Biopharma to Merge 17
Licensing Agreements 19
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 19
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 20
Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 22
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 24
Equity Offering 25
Akebia Therapeutics Prices Public Offering of Shares for up to USD89 Million 25
Akebia Therapeutics Raises USD66.7 Million in Public Offering of Shares 26
Akebia Therapeutics Raises USD25.7 million Public Offering of Shares 28
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 29
Akebia Therapeutics Files Registration Statement for Public Offering of Shares for up to USD100 Million 30
Akebia Therapeutics Raises USD75 Million in Public Offering of Shares 31
Akebia Therapeutics Raises USD69 Million in Public Offering of Shares 33
Akebia Therapeutics Completes IPO For US$115 Million 34
Akebia Therapeutics Inc – Key Competitors 36
Akebia Therapeutics Inc – Key Employees 37
Akebia Therapeutics Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 08, 2018: Akebia Therapeutics announces second quarter 2018 financial results 39
May 09, 2018: Akebia Therapeutics Announces First Quarter 2018 Financial Results 41
Mar 12, 2018: Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results 42
Nov 08, 2017: Akebia Therapeutics Announces Third Quarter 2017 Financial Results 44
Aug 08, 2017: Akebia Announces Second Quarter 2017 Financial Results 45
May 09, 2017: Akebia Announces First Quarter 2017 Financial Results 46
Mar 06, 2017: Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results 47
Corporate Communications 49
Aug 28, 2018: Akebia Therapeutics names Cynthia Smith to its board of directors 49
May 25, 2017: Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer 50
Clinical Trials 51
Feb 12, 2018: Akebia Therapeutics Provides Update on Vadadustat Development Program 51
Jan 04, 2018: Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease 53
Nov 01, 2017: Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia 54
Sep 26, 2017: Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease 55
May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents 56
Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akebia Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Akebia Therapeutics Raises US$41 Million In Series C Financing 13
Akebia Therapeutics Secures Additional US$4.1 Million In Series B Financing 15
Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 16
Akebia Therapeutics and Keryx Biopharma to Merge 17
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 19
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 20
Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 22
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 24
Akebia Therapeutics Prices Public Offering of Shares for up to USD89 Million 25
Akebia Therapeutics Raises USD66.7 Million in Public Offering of Shares 26
Akebia Therapeutics Raises USD25.7 million Public Offering of Shares 28
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 29
Akebia Therapeutics Files Registration Statement for Public Offering of Shares for up to USD100 Million 30
Akebia Therapeutics Raises USD75 Million in Public Offering of Shares 31
Akebia Therapeutics Raises USD69 Million in Public Offering of Shares 33
Akebia Therapeutics Completes IPO For US$115 Million 34
Akebia Therapeutics Inc, Key Competitors 36
Akebia Therapeutics Inc, Key Employees 37
Akebia Therapeutics Inc, Subsidiaries 38

List of Figures
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Akebia Therapeutics Inc (AKBA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gestamp Renewable Industries:電力:M&Aディール及び事業提携情報
    Summary Gestamp Renewable Industries, a subsidiary of Corporacion Gestamp SL, is a renewable energy service provider. The company offers development, promotion, construction and operation of electric generation power plants from biomass. It offers production, logistics, packaging, generation, design …
  • Nectar Lifesciences Ltd (NECLIFE):企業の財務・戦略的SWOT分析
    Summary Nectar Lifesciences Ltd (NecLife) is a research driven pharmaceutical company that manufactures active pharmaceutical ingredients (APIs). The company provides contract research and manufacturing services such as process development and optimization, process scale up and validation, multi kil …
  • Verizon Communications Inc (VZ):企業の財務・戦略的SWOT分析
    Verizon Communications Inc (VZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Huesker Synthetic Gmbh
    Huesker Synthetic Gmbh - Strategy, SWOT and Corporate Finance Report Summary Huesker Synthetic Gmbh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Thermo Fisher Scientific Inc (TMO):医療機器:M&Aディール及び事業提携情報
    Summary Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of equipment, analytical instruments, reagents and consumables, software and services to tackle complex analytical challenges in research, diagnostics and clinical laboratories. It offers solutions for cellular analysis and biology, …
  • I Grandi Viaggi Spa:企業の戦略・SWOT・財務分析
    I Grandi Viaggi Spa - Strategy, SWOT and Corporate Finance Report Summary I Grandi Viaggi Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Sahara Energy Ltd (SAH):石油・ガス:M&Aディール及び事業提携情報
    Summary Sahara Energy Ltd (Sahara Energy) is an oil and gas exploration and development company that acquires, exploits, explores, and develops oil and natural gas reserves in Western Canada. The company evaluates oil and gas exploration properties in Canada. It plans on growing through the drill bi …
  • Concordia International Corp (CXR)-製薬・医療分野:企業M&A・提携分析
    Summary Concordia International Corp (Concordia), formerly Concordia Healthcare Corp is a healthcare products provider that offers orphan drugs. The company undertakes the management and acquisition of legacy pharmaceutical products, orphan drugs and medical devices for diabetics. Its products compr …
  • BioFactura Inc-製薬・医療分野:企業M&A・提携分析
    Summary BioFactura Inc (Biofactura) is a biosimilars manufacturer that discovers, develops and markets biodefense drugs and client selected novel drugs. The company offers contract services such as process development, stable cell lines, and manufacturing. Its stable cell lines offers stable mammali …
  • Woodside Petroleum Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Woodside Petroleum Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Woodside Petroleum Ltd (Woodside) is an independent oil and gas company that explores, develops, produces and supplies energy. It explores and produces oil and gas from a portfolio of faciliti …
  • Philippine Long Distance Telephone Company:企業の戦略・SWOT・財務情報
    Philippine Long Distance Telephone Company - Strategy, SWOT and Corporate Finance Report Summary Philippine Long Distance Telephone Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Premaitha Health Plc (NIPT):医療機器:M&Aディール及び事業提携情報
    Summary Premaitha Health Plc (Premaitha Health), formerly Vialogy Plc, is a molecular diagnostics company, which focuses on the development of genetic screening tests including novel tests for non-invasive prenatal screening (NIPT). Its flagship product, the IONA test is an advanced NIPT test that a …
  • Barclaycard:企業の戦略・SWOT・財務情報
    Barclaycard - Strategy, SWOT and Corporate Finance Report Summary Barclaycard - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Direct Flow Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Direct Flow Medical Inc (Direct Flow) is a medical device company that develops novel transcatheter heart valve technologies. The company provides transcatheter aortic valve implantation device without contrast. It also provides direct flow medical system, a technology for controlled and rel …
  • The Warehouse Group Ltd (WHS):企業の財務・戦略的SWOT分析
    The Warehouse Group Ltd (WHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Cargolux Airlines International S.A.:企業の戦略的SWOT分析
    Cargolux Airlines International S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Thomas Cook Group plc:企業の戦略・SWOT・財務情報
    Thomas Cook Group plc - Strategy, SWOT and Corporate Finance Report Summary Thomas Cook Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Paradigm Biopharmaceuticals Ltd (PAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Paradigm Biopharmaceuticals Ltd (Paradigm Biopharma) is a biopharmaceutical company. The company focused on research and development of therapeutic products for human use. It offers pentosan polysulphate sodium (PPS) drugs for new orthopaedic and respiratory applications. Paradigm Biopharma …
  • Taiflex Scientific Co., Ltd. (8039):企業の財務・戦略的SWOT分析
    Taiflex Scientific Co., Ltd. (8039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Tepha Inc:企業の製品パイプライン分析
    Summary Tepha Inc (Tepha) is a medical device firm that develops and commercializes biomaterial technology products. The firm offers products such as absorbable monofilament suture, absorbable monofilament mesh, composite mesh and absorbable surgical film. It also provides platforms including absorb …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆